C4 Therapeutics, Inc.
CCCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $36 | $21 | $31 | $46 |
| % Growth | 71.4% | -33.3% | -32.1% | – |
| Cost of Goods Sold | $0 | $8 | $0 | $0 |
| Gross Profit | $36 | $13 | $31 | $46 |
| % Margin | 100% | 62.7% | 100% | 100% |
| R&D Expenses | $111 | $118 | $118 | $95 |
| G&A Expenses | $42 | $42 | $43 | $33 |
| SG&A Expenses | $42 | $42 | $43 | $33 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | -$8 | $0 | $0 |
| Operating Expenses | $155 | $152 | $161 | $128 |
| Operating Income | -$120 | -$139 | -$130 | -$82 |
| % Margin | -336.1% | -669.8% | -416.6% | -179.4% |
| Other Income/Exp. Net | $14 | $8 | $1 | -$2 |
| Pre-Tax Income | -$105 | -$131 | -$128 | -$84 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$105 | -$132 | -$128 | -$84 |
| % Margin | -296% | -638.3% | -412.2% | -183.2% |
| EPS | -1.52 | -2.67 | -2.62 | -1.82 |
| % Growth | 43.1% | -1.9% | -44% | – |
| EPS Diluted | -1.52 | -2.67 | -2.62 | -1.82 |
| Weighted Avg Shares Out | 69 | 50 | 49 | 46 |
| Weighted Avg Shares Out Dil | 69 | 50 | 49 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $10 | $4 | $0 |
| Interest Expense | $0 | $1 | $2 | $2 |
| Depreciation & Amortization | $2 | $8 | $2 | $1 |
| EBITDA | -$103 | -$122 | -$124 | -$80 |
| % Margin | -290.5% | -588.3% | -399.7% | -175.3% |